ASMER1: A Potential Drug Target for TGF-β and NF-kappa-B-mediated Diseases

Target Name: ASMER1

NCBI ID: G107987295

ASMER1

Other Name(s): ASMER-1 | LINC02246 | adipocyte associated metabolic related lncRNA 1 | Long intergenic non-protein coding RNA 2246

ASMER1: A Potential Drug Target for TGF-β and NF-kappa-B-mediated Diseases

ASMER1 (ASMER-1) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the ASMER family of proteins, which are known for their role in the regulation of cell signaling pathways.

ASMER1 has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these conditions is not well understood, but its expression is known to be affected by the activity of several intracellular signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT.

One of the key functions of ASMER1 is its role in the regulation of TGF-β signaling pathway. TGF-β is a cytokine that plays a critical role in the development and maintenance of tissues, and is involved in a wide range of physiological processes, including cell growth, differentiation, and inflammation.

ASMER1 has been shown to regulate the activity of TGF-β by interacting with its extracellular domain, which contains several conserved 伪-helical structures. This interaction between ASMER1 and TGF-β allows ASMER1 to regulate the activity of TGF-β and influence the cell signaling pathways that are involved in TGF-β-mediated processes.

ASMER1 has also been shown to play a role in the regulation of NF-kappa-B signaling pathway. NF-kappa-B is a transcription factor that is involved in the regulation of gene expression and cell signaling pathways. It is activated by various cytokines and stressors, and has been implicated in a wide range of diseases, including cancer and neurodegenerative disorders.

ASMER1 has been shown to regulate the activity of NF-kappa-B by interacting with its amino terminal domain. This interaction between ASMER1 and NF-kappa-B allows ASMER1 to regulate the activity of NF-kappa-B and influence the cell signaling pathways that are involved in NF-kappa-B-mediated processes.

In addition to its role in the regulation of TGF-β and NF-kappa-B signaling pathways, ASMER1 has also been shown to play a role in the regulation of PI3K/AKT signaling pathway. PI3K/AKT is a signaling pathway that is involved in the Regulation of cell signaling pathways, including cell survival and angiogenesis.

ASMER1 has been shown to regulate the activity of PI3K/AKT by interacting with its carboxy terminal domain. This interaction between ASMER1 and PI3K/AKT allows ASMER1 to regulate the activity of PI3K/AKT and influence the cell signaling pathways that are involved in PI3K/ AKT-mediated processes.

ASMER1 has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression is known to be affected by the activity of several intracellular signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT.

In conclusion, ASMER1 is a protein that is involved in the regulation of cell signaling pathways and has been identified as a potential drug target or biomarker for several diseases. Further research is needed to fully understand its role in these conditions and to develop effective treatments.

Protein Name: Adipocyte Associated Metabolic Related LncRNA 1

The "ASMER1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASMER1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets